Thursday 10th September
09:10 to 09:20
The role of the interdisciplinary "Aortic Team" in optimising the emergency transfer of patients and its impact on outcome
Marcus Brooks, North Bristol NHS Trust, UK
09:20 to 09:30
Imaging surveillance after Type B dissection: How often, what to look for, and what we may be missing
Federica Catapano, Humanitas Research Hospital, Milan, Italy
09:30 to 09:40
Contemporary analysis techniques for the multimodal data and how it can inform the management of Type B aortic dissection
Kak Khee Yeung, University of Amsterdam, Netherlands
Kak Khee Yeung
09:40 to 09:50
Guidelines vs reality: Where evidence fails in Type B aortic dissection
Anders Wanhainen, University of Uppsala, Sweden
Anders Wanhainen
09:50 to 10:05
Perspectives on survivorship and surveillance
Martin Hilton, Patient representative, Aortic Dissection Charitable Trust
Tara Mastracci, Barts Health, London, UK
Tara Mastracci , Martin Hilton
10:05 to 10:30
Discussion
10:30 to 10:45
Endovascular reconstruction of the dissected ascending aorta and arch: Defining strategy in the era of fenestrated and branched repair and what comes next
Speaker: Stéphan Haulon, Hopital Marie Lannelongue, Paris, France
Introduced by Bijan Modarai
Vote of thanks by Tara Mastracci
Stephan Haulon
11:15 to 11:25
From open to hybrid to total endovascular: Navigating the transition in the treatment of the dissected aortic arch
Nimesh Desai, University of Pennsylvania, USA
Nimesh Desai
11:25 to 11:35
Do we need a more effective solution for chronic false lumen sac management?
Gustavo Oderich, Baylor Medicine Centre for Aortic Surgery, USA
Gustavo Oderich
11:35 to 12:15
Strategy & Future Scoping Roundtable
Lead discussant: Tim Resch, University of Copenhagen, Denmark
Expert panel: Anders Wanhainen, Stéphan Haulon, Nimesh Desai, Eric Roselli, Tara Mastracci, Kak Khee Yeung
- Remote monitoring in aortic dissection
- Is remodelling for chronic dissection important and, if so, how can we achieve it?
- Functional and haemodynamic assessment of the dissected aorta, with potential AI integration
- Endovascular technologies in connective tissue disease
12:15 to 12:35
Integrated Aortic Team Debate
Convenors: Tara Mastracci & Barend Mees
Panel: Nimesh Desai, Eric Roselli, Stéphan Haulon & Gustavo Oderich
One Aorta. Four Experts. One decision?
Each expert present, defends and critiques their preferred open or endovascular strategy for the same complex aortic dissection
Tara Mastracci , Barend Mees , Nimesh Desai , Eric Roselli , Stéphan Haulon , Gustavo Oderich
12:35 to 12:45
Cook Medical Guest Lecture
13:35 to 13:50
Off-the-shelf endovascular solutions will replace custom and physician-modified devices in aortic dissection
For: Tim Resch, University of Copenhagen, Denmark
Against: Gustavo Oderich, Baylor Medicine Centre for Aortic Surgery, USA
Tim Resch , Gustavo Oderich
13:50 to 14:00
Malperfusion in Type A aortic dissection: When, how and what to fix first
Eric Roselli, Cleveland Clinic, USA
Eric Roselli
14:00 to 14:10
The hostile access: Navigating true lumen collapse, iliac malperfusion, and the inaccessible branch vessel
Barend Mees, Maastricht Heart+Vascular Center, Maastricht, Netherlands
Barend Mees
14:10 to 14:20
Complications of TEVAR in dissection: Risk factors, prevention, recognition and bailout strategies
Stephen Cheng, University of Hong Kong
Stephen Cheng
14:20 to 14:40
Discussion
14:40 to 15:10
Interactive MDT simulation
Cases for discussion: Becky Sandford & Mohamed Abdelhalim
Expert panel: Judith Partridge, Pano Gkoutzios, Eric Roselli, Colin Bicknell, Michael Sabetai, Stephen Cheng
Becky Sandford , Jude Partridge , Panos Gkoutzios , Eric Roselli , Colin Bicknell , Stephen Cheng
15:10 to 15:20
Gore Guest Lecture: Optimising Aortic Arch Treatment: Clinical Experience with the GORE® TAG® Thoracic Branch Endoprosthesis
David Murray, Manchester Vascular Centre, Manchester Royal Infirmary, UK
15:50 to 16:10
Global roundtable on evidence for managing uncomplicated Type B dissection
3 minute update on uncomplicated TBAD trials
Moderator: Kevin Mani
Panel: Firas Mussa, Colin Bicknell, Jacob Budtz-Lilly
Discussion points:
- Medical optimisation, how is this being achieved in practice in the trials?
- Does device choice and timing of intervention really change outcomes?
- What are we learning from the patients not included in the trials? Data from screening
- How generalisable are these trials - management of dissections and centres of expertise
16:10 to 16:25
IMH is not a separate disease: It should be treated the same as dissection
For: Firas Mussa, UTHealth Houston McGovern Medical School, USA
Against: Jacob-Budtz-Lilly, Aarhus University, Denmark
Firas Mussa , Jacob Budtz-Lilly
16:25 to 16:40
When treatment creates the next problem
- Distal stent-induced new entry (dSINE): Kak Khee Yeung, University of Amsterdam, Netherlands
- Extensive aortic coverage and altering stiffness: Anders Wanhainen, University of Uppsala, Sweden
16:40 to 16:50
The STABILISE registry: What have we learnt?
Germano Melissano, "Vita-Salute” San Raffaele, University of Milan, Italy
Germano Melissano
16:50 to 17:00
Trends in epidemiology and outcome of aortic dissections - a national population-based study
Kevin Mani, Uppsala University, Sweden
Kevin Mani
17:00 to 17:25
Discussion